11:49 AM EST - Valeant Pharmaceuticals International, Inc : Announced that its wholly-owned subsidiary, Bausch + Lomb, and Nicox S.A. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO(TM) (latanoprostene bunod ophthalmic solution 0.024%), an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. Valeant Pharmaceuticals International, Inc
shares T.VRX are trading down $12.79 at $290.75.
